论文部分内容阅读
采用双抗夹心酶联免疫吸附试验（ＥＬＩＳＡ）测定了３４ 例急性脑梗塞患者发病后２４ 小时、７２小时、１ 周及２ 周的血清可溶性细胞间粘附分子－１（ｓＩＣＡＭ－１）浓度。结果示发病１ 周内ｓＩＣＡＭ－１浓度逐渐上升，于１ 周时达高峰，２ 周后明显下降。发病后７２ 小时ｓＩＣＡＭ－１ 水平与脑梗塞体积呈正相关（Ｐ＜０．０１）；但与病情严重程度无明显相关关系（Ｐ＞ ０．０５）。认为ｓＩＣＡＭ－１ 在急性脑梗塞病程中呈动态变化，ｓＩＣＡＭ－１ 参与了脑梗塞的病理发展过程；血清ｓＩＣＡＭ－１ 浓度可作为监测急性脑梗塞白细胞介导的脑损伤的一个指标，与脑梗塞体积呈正相关。
Serum soluble intercellular adhesion molecule-1 (sICAM-1) concentrations were measured at 24, 72, 1 and 2 weeks after onset in 34 patients with acute cerebral infarction using double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) The results showed that the incidence of sICAM-1 concentration gradually increased within 1 week, peaked at 1 week, significantly decreased after 2 weeks. The level of sICAM-1 at 72 hours after onset was positively correlated with the volume of cerebral infarction (P <0.01). However, there was no significant correlation between the level of sICAM-1 and the severity of illness (P> 0.05). SICAM-1 is involved in the pathological process of cerebral infarction. The concentration of sICAM-1 in serum can be used as an index to monitor the white blood cell-mediated brain injury in acute cerebral infarction, The volume was positively correlated.